Research Analysts Set Expectations for TBPH Q1 Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Equities researchers at Zacks Research issued their Q1 2028 earnings per share (EPS) estimates for shares of Theravance Biopharma in a research note issued on Thursday, April 9th. Zacks Research analyst Team forecasts that the biopharmaceutical company will post earnings per share of $0.01 for the quarter. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma’s FY2028 earnings at $0.59 EPS.

Several other analysts also recently issued reports on the company. B. Riley Financial lifted their target price on Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a research note on Tuesday, April 7th. Weiss Ratings downgraded Theravance Biopharma from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday. Wall Street Zen raised Theravance Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. HC Wainwright lifted their price objective on Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Finally, Oppenheimer downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Theravance Biopharma currently has an average rating of “Moderate Buy” and a consensus price target of $21.83.

Theravance Biopharma Trading Up 0.6%

Shares of TBPH opened at $16.60 on Monday. The business’s 50 day moving average is $16.62 and its 200 day moving average is $17.11. The company has a market capitalization of $854.73 million, a PE ratio of 8.18 and a beta of 0.17. Theravance Biopharma has a 12-month low of $8.33 and a 12-month high of $21.03.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $13.96, for a total value of $433,695.32. Following the sale, the senior vice president owned 232,699 shares of the company’s stock, valued at $3,248,478.04. The trade was a 11.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Theravance Biopharma

Large investors have recently modified their holdings of the stock. Baader Bank Aktiengesellschaft bought a new position in shares of Theravance Biopharma during the 3rd quarter valued at approximately $781,000. JPMorgan Chase & Co. increased its position in shares of Theravance Biopharma by 78.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 213,104 shares of the biopharmaceutical company’s stock valued at $3,111,000 after purchasing an additional 93,591 shares during the last quarter. Hillsdale Investment Management Inc. bought a new position in shares of Theravance Biopharma during the 3rd quarter valued at approximately $4,536,000. Inspire Investing LLC bought a new position in shares of Theravance Biopharma during the 3rd quarter valued at approximately $1,074,000. Finally, Assenagon Asset Management S.A. increased its position in shares of Theravance Biopharma by 1,629.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock valued at $6,055,000 after purchasing an additional 390,735 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma News Summary

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Zacks Research sharply raised multi-quarter and full‑year EPS forecasts for TBPH (notably FY2026 raised to $0.80 from a prior loss estimate and FY2027 to $0.28), and reiterated a “Strong-Buy” view — an across‑the‑board upgrade to near‑term profitability that can support higher valuation and buying interest. Zacks Research coverage summary
• Positive Sentiment: Wall Street Zen upgraded TBPH to “Strong‑Buy”, adding independent positive analyst sentiment which can boost investor confidence and momentum. Theravance Biopharma Rating Increased to Strong-Buy at Wall Street Zen
• Negative Sentiment: Pomerantz LLP issued an investor alert saying it is investigating claims on behalf of Theravance investors — a potential securities litigation risk that can increase uncertainty, legal costs and volatility for the stock. Pomerantz investor alert

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.